Yael Cohen, MD, on Promising Therapeutics in the Heavily Pretreated Myeloma Space


Yael Cohen, MD, sat down with CancerNetwork® to spotlight a number of promising treatments that are under investigation for patients with heavily-pretreated multiple myeloma.

In an interview with CancerNetwork®, Yael Cohen, MD, a senior physician in the Department of Hematology at Tel-Aviv Sourasky Medical Center, touched on a number of promising therapeutic agents for the treatment of heavily-pretreated multiple myeloma.

In addition to highlighting important clinical findings that read out at the 2021 American Society for Hematology Annual Meeting & Exposition, she discussed potential targeted therapies for multiple myeloma and the need to better select patients for treatment utilizing molecular tools.


This ASH meeting was a very good thing [in terms of] news for myeloma. I already mentioned CARTITUDE-1, which showed outstanding results as far as the durability of response in these very heavily pretreated patients. There have also been some interesting presentations on bispecific T-cell engagers, specifically antibodies; several drugs were shown from Regeneron. There's talquetamab and teclistimab, so there are several targets. There are targets to BCMA and there are other targets that are also being explored. We are seeing very nice and deep responses, again, in very heavily pretreated patients. We'll have to learn which patient needs to get which treatment and when, and we have now all these possibilities. We'll have to start getting more wise about the selection of the best treatment per patient perhaps using molecular tools that will help us understand in a more analytic way how to select the combination drug for a given patients.

Related Videos
A panel of 4 experts on multiple myeloma seated at a long table
A panel of 4 experts on multiple myeloma seated at a long table
Experts on MM
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Patients with mismatch repair proficient, newly diagnosed, advanced or recurrent endometrial cancer may have enhanced benefit with the addition of olaparib to durvalumab.
Craig Cole, MD, an expert on multiple myeloma, presenting slides
Experts on MM
Related Content